{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:39:21Z","timestamp":1792787961400,"version":"4.5.0"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.hoc.2026.09.013","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:14:59Z","timestamp":1792786499000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Emerging Antiplatelet Agents"],"prefix":"10.1016","author":[{"given":"Mushood","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samarth","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behnood","family":"Bikdeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.hoc.2026.09.013_bib1","doi-asserted-by":"crossref","first-page":"44","DOI":"10.5334\/gh.1323","article-title":"Global prevalence of aspirin use for primary prevention of cardiovascular disease: a cross-sectional study of nationally representative, individual-level data","volume":"19","author":"Yoo","year":"2024","journal-title":"Glob Heart"},{"issue":"0","key":"10.1016\/j.hoc.2026.09.013_bib2","article-title":"Contemporary trends in high-potency P2Y12 receptor inhibitor use among patients with acute myocardial infarction undergoing percutaneous coronary intervention","volume":"0","author":"Fath","year":"2026","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"10.1016\/j.hoc.2026.09.013_bib3","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.7326\/M24-0427","article-title":"Aspirin use prevalence for cardiovascular disease prevention among U.S. adults from 2012 to 2021","volume":"177","author":"Gupta","year":"2024","journal-title":"Ann Intern Med"},{"issue":"7329","key":"10.1016\/j.hoc.2026.09.013_bib4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.hoc.2026.09.013_bib5","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41569-018-0049-1","article-title":"Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention","volume":"15","author":"Capodanno","year":"2018","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"10.1016\/j.hoc.2026.09.013_bib6","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41569-018-0110-0","article-title":"Platelet biology and functions: new concepts and clinical perspectives","volume":"16","author":"van der Meijden","year":"2019","journal-title":"Nat Rev Cardiol"},{"issue":"22","key":"10.1016\/j.hoc.2026.09.013_bib7","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1161\/CIRCULATIONAHA.120.045465","article-title":"Antithrombotic therapy for atherosclerotic cardiovascular disease risk mitigation in patients with coronary artery disease and diabetes mellitus","volume":"142","author":"Capodanno","year":"2020","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.hoc.2026.09.013_bib8","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s12471-021-01604-4","article-title":"Long-term residual cardiovascular risk after acute coronary syndrome: antithrombotic treatment options","volume":"30","author":"Chan Pin Yin","year":"2022","journal-title":"Neth Heart J"},{"key":"10.1016\/j.hoc.2026.09.013_bib9","author":"Sadeghipour"},{"issue":"4","key":"10.1016\/j.hoc.2026.09.013_bib10","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.024159","article-title":"CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention in diverse clinical settings","volume":"11","author":"Beitelshees","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"10.1016\/j.hoc.2026.09.013_bib11","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1161\/01.CIR.103.2.201","article-title":"Increased mortality with oral platelet glycoprotein IIb\/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials","volume":"103","author":"Chew","year":"2001","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.hoc.2026.09.013_bib12","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0002-9343(02)01106-3","article-title":"The failure of orally administered glycoprotein IIb\/IIIa inhibitors to prevent recurrent cardiac events","volume":"112","author":"Newby","year":"2002","journal-title":"Am J Med"},{"issue":"15","key":"10.1016\/j.hoc.2026.09.013_bib13","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","article-title":"Vorapaxar in the secondary prevention of atherothrombotic events","volume":"366","author":"Morrow","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.hoc.2026.09.013_bib14","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1161\/CIRCINTERVENTIONS.111.964197","volume":"5","author":"Welsh","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"issue":"Suppl 1","key":"10.1016\/j.hoc.2026.09.013_bib15","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1538-7836.2011.04361.x","article-title":"Platelet adhesion and activation mechanisms in arterial thrombosis and ischaemic stroke","volume":"9","author":"Nieswandt","year":"2011","journal-title":"J Thromb Haemostasis"},{"issue":"4","key":"10.1016\/j.hoc.2026.09.013_bib16","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.jtha.2024.12.003","article-title":"New targets for antithrombotic medications: seeking to decouple thrombosis from hemostasis","volume":"23","author":"Barnes","year":"2025","journal-title":"J Thromb Haemostasis"},{"issue":"4","key":"10.1016\/j.hoc.2026.09.013_bib17","first-page":"319","article-title":"Mechanism action of platelets and crucial blood coagulation pathways in hemostasis","volume":"11","author":"Periayah","year":"2017","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"issue":"7","key":"10.1016\/j.hoc.2026.09.013_bib18","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1093\/cvr\/cvz070","article-title":"Platelets in cardiac ischaemia\/reperfusion injury: a promising therapeutic target","volume":"115","author":"Ziegler","year":"2019","journal-title":"Cardiovasc Res"},{"issue":"12","key":"10.1016\/j.hoc.2026.09.013_bib19","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1016\/j.jtha.2023.09.013","article-title":"Antiplatelet strategies: past, present & future","volume":"21","author":"Stanger","year":"2023","journal-title":"J Thromb Haemostasis"},{"issue":"8","key":"10.1016\/j.hoc.2026.09.013_bib20","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1161\/CIRCULATIONAHA.123.067283","article-title":"Safety and efficacy of ticagrelor monotherapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention: an individual patient data meta-analysis of TWILIGHT and TICO randomized trials","volume":"149","author":"Baber","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.hoc.2026.09.013_bib21","article-title":"P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials","volume":"373","author":"Valgimigli","year":"2021","journal-title":"BMJ"},{"issue":"13","key":"10.1016\/j.hoc.2026.09.013_bib22","first-page":"e771","article-title":"ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American college of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"151","author":"Rao","year":"2025","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.hoc.2026.09.013_bib23","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jacc.2023.04.051","article-title":"P2Y12 inhibitor or aspirin monotherapy for secondary prevention of coronary events","volume":"82","author":"Gragnano","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"10.1016\/j.hoc.2026.09.013_bib24","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.jacc.2012.02.026","volume":"59","author":"Trenk","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.hoc.2026.09.013_bib25","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/jama.2011.290","article-title":"Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial","volume":"305","author":"Price","year":"2011","journal-title":"JAMA"},{"issue":"10104","key":"10.1016\/j.hoc.2026.09.013_bib26","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(17)32155-4","article-title":"Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial","volume":"390","author":"Sibbing","year":"2017","journal-title":"Lancet"},{"issue":"27","key":"10.1016\/j.hoc.2026.09.013_bib27","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/eurheartj\/ehv104","article-title":"Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention","volume":"36","author":"Aradi","year":"2015","journal-title":"Eur Heart J"},{"issue":"17","key":"10.1016\/j.hoc.2026.09.013_bib28","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1907096","article-title":"A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI","volume":"381","author":"Claassens","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.hoc.2026.09.013_bib29","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.2020.12443","article-title":"Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial","volume":"324","author":"Pereira","year":"2020","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.hoc.2026.09.013_bib30","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1056\/NEJMoa2504650","article-title":"Low-dose aspirin for PI3K-Altered localized colorectal cancer","volume":"393","author":"Martling","year":"2025","journal-title":"N Engl J Med"},{"issue":"10240","key":"10.1016\/j.hoc.2026.09.013_bib31","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/S0140-6736(20)30366-4","article-title":"Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial","volume":"395","author":"Burn","year":"2020","journal-title":"Lancet"},{"issue":"17_suppl","key":"10.1016\/j.hoc.2026.09.013_bib32","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA3511","article-title":"Aspirin as secondary prevention for colorectal cancer liver metastases (ASAC): a multicenter, randomized, double-blind, placebo-controlled, phase 3 trial","volume":"43","author":"Yaqub","year":"2025","journal-title":"J Clin Oncol"},{"issue":"8060","key":"10.1016\/j.hoc.2026.09.013_bib33","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/s41586-025-08626-7","article-title":"Aspirin prevents metastasis by limiting platelet TXA2 suppression of T cell immunity","volume":"640","author":"Yang","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.hoc.2026.09.013_bib68","doi-asserted-by":"crossref","first-page":"vag071","DOI":"10.1093\/ehjcvp\/pvag071","article-title":"Coated or chewable Aspirin and a hybrid air pollution mitigation strategy in patients with atherosclerotic disease: Rationale and Design of the COATED-AIR Randomized Trial","author":"Bikdeli","year":"2026","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"7","key":"10.1016\/j.hoc.2026.09.013_bib34","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/psp4.12641","article-title":"Pharmacokinetic\/pharmacodynamic modeling of drug interactions at the P2Y12 receptor between selatogrel and oral P2Y12 antagonists","volume":"10","author":"Henrich","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"33","key":"10.1016\/j.hoc.2026.09.013_bib35","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1093\/eurheartj\/ehz807","article-title":"Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes","volume":"41","author":"Storey","year":"2020","journal-title":"Eur Heart J"},{"issue":"20","key":"10.1016\/j.hoc.2026.09.013_bib36","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1016\/j.jacc.2020.03.059","article-title":"Subcutaneous selatogrel inhibits platelet aggregation in patients with acute myocardial infarction","volume":"75","author":"Sinnaeve","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"Pt 4","key":"10.1016\/j.hoc.2026.09.013_bib37","article-title":"Promising clopidogrel analogs may overcome clopidogrel resistance: 2025 update","volume":"242","author":"Xie","year":"2025","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.hoc.2026.09.013_bib38","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/bph.17355","article-title":"The first in-human study to evaluate the antiplatelet properties of the clopidogrel conjugate DT-678 in acute coronary syndrome patients and healthy volunteers","volume":"182","author":"Liu","year":"2025","journal-title":"Br J Pharmacol"},{"issue":"8","key":"10.1016\/j.hoc.2026.09.013_bib39","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1093\/ehjcvp\/pvac026","article-title":"Antiplatelet effect, safety, and pharmacokinetics of vicagrel in patients with coronary artery disease undergoing percutaneous coronary intervention","volume":"8","author":"Zhao","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.hoc.2026.09.013_bib40","doi-asserted-by":"crossref","first-page":"643","DOI":"10.3389\/fphar.2018.00643","article-title":"Evaluation of tolerability, pharmacokinetics and pharmacodynamics of vicagrel, a novel P2Y12 antagonist, in healthy Chinese volunteers","volume":"9","author":"Li","year":"2018","journal-title":"Front Pharmacol"},{"issue":"9","key":"10.1016\/j.hoc.2026.09.013_bib41","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1111\/bcp.14296","article-title":"Impacts of CYP2C19 genetic polymorphisms on bioavailability and effect on platelet adhesion of vicagrel, a novel thienopyridine P2Y12 inhibitor","volume":"86","author":"Zhang","year":"2020","journal-title":"Br J Clin Pharmacol"},{"issue":"Supplement_1","key":"10.1016\/j.hoc.2026.09.013_bib42","doi-asserted-by":"crossref","first-page":"ehae666","DOI":"10.1093\/eurheartj\/ehae666.3343","article-title":"Phase I results of both IV and oral administration for CG-0255: a novel fast-acting antiplatelet drug with a new activation pathway","volume":"45","author":"Chen","year":"2024","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.hoc.2026.09.013_bib43","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2024-003088","article-title":"Phase 1 study of novel anti-platelet agent to overcome pharmacogenomic limitations of clopidogrel","volume":"12","author":"Pareek","year":"2025","journal-title":"Open Heart"},{"issue":"17","key":"10.1016\/j.hoc.2026.09.013_bib44","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.016552","article-title":"First human use of RUC-4: a nonactivating second-generation small-molecule platelet glycoprotein IIb\/IIIa (integrin \u03b1IIb\u03b23) inhibitor designed for subcutaneous point-of-care treatment of ST-Segment\u2013Elevation myocardial infarction","volume":"9","author":"Kereiakes","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.hoc.2026.09.013_bib45","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2500268","article-title":"Zalunfiban at first medical contact for ST-Elevation myocardial infarction","volume":"5","author":"Van\u2019t Hof","year":"2026","journal-title":"NEJM Evid"},{"issue":"4","key":"10.1016\/j.hoc.2026.09.013_bib46","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s11239-023-02867-x","article-title":"Comparison of the effects of the GPIIb-IIIa antagonist Zalunfiban and the P2Y12 antagonist selatogrel on platelet aggregation","volume":"56","author":"Curry","year":"2023","journal-title":"J Thromb Thrombolysis"},{"issue":"9","key":"10.1016\/j.hoc.2026.09.013_bib47","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.3390\/biomedicines12092023","article-title":"Current and future roles of glycoprotein IIb\u2013IIIa inhibitors in primary angioplasty for ST-Segment elevation myocardial infarction","volume":"12","author":"De Luca","year":"2024","journal-title":"Biomedicines"},{"issue":"9","key":"10.1016\/j.hoc.2026.09.013_bib48","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/jcph.1616","article-title":"Population pharmacokinetic\/pharmacodynamic modeling of glenzocimab (ACT017) a glycoprotein VI inhibitor of collagen-induced platelet aggregation","volume":"60","author":"Renaud","year":"2020","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.hoc.2026.09.013_bib49","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1474-4422(23)00427-1","article-title":"Safety and efficacy of platelet glycoprotein VI inhibition in acute ischaemic stroke (ACTIMIS): a randomised, double-blind, placebo-controlled, phase 1b\/2a trial","volume":"23","author":"Mazighi","year":"2024","journal-title":"Lancet Neurol"},{"issue":"0","key":"10.1016\/j.hoc.2026.09.013_bib50","article-title":"Glenzocimab efficacy and safety added to intravenous thrombolysis with or without mechanical thrombectomy in patients with acute ischemic stroke. ACTISAVE: a prospective, randomized, double-blind study","volume":"0","author":"K\u00f6hrmann","year":"2026","journal-title":"Stroke"},{"key":"10.1016\/j.hoc.2026.09.013_bib51","article-title":"Glenzocimab for reperfusion in the setting of endovascular therapy for brain infarction: GREEN study","author":"Mazighi","year":"2025","journal-title":"J Neurointerventional Surg"},{"issue":"7","key":"10.1016\/j.hoc.2026.09.013_bib52","doi-asserted-by":"crossref","first-page":"C757","DOI":"10.1152\/ajpcell.00060.2012","article-title":"The dimeric platelet collagen receptor GPVI-Fc reduces platelet adhesion to activated endothelium and preserves myocardial function after transient ischemia in mice","volume":"303","author":"Sch\u00f6nberger","year":"2012","journal-title":"Am J Physiol Cell Physiol"},{"issue":"17","key":"10.1016\/j.hoc.2026.09.013_bib53","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1161\/CIRCULATIONAHA.110.980623","article-title":"Novel antiplatelet drug revacept (Dimeric Glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans","volume":"123","author":"Ungerer","year":"2011","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.hoc.2026.09.013_bib54","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1001\/jamacardio.2021.0475","volume":"6","author":"Mayer","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"9","key":"10.1016\/j.hoc.2026.09.013_bib55","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1161\/STROKEAHA.121.037006","article-title":"Revacept, an inhibitor of Platelet adhesion in symptomatic carotid stenosis: a multicenter randomized phase II trial","volume":"53","author":"Uphaus","year":"2022","journal-title":"Stroke"},{"issue":"18","key":"10.1016\/j.hoc.2026.09.013_bib56","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1021\/bi9927078","article-title":"Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets","volume":"39","author":"Covic","year":"2000","journal-title":"Biochemistry"},{"issue":"2","key":"10.1016\/j.hoc.2026.09.013_bib57","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1161\/ATVBAHA.117.310104","article-title":"PAR4 (Protease-Activated receptor 4) antagonism with BMS-986120 inhibits human Ex vivo thrombus formation","volume":"38","author":"Wilson","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"10.1016\/j.hoc.2026.09.013_bib58","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1161\/ATVBAHA.120.314960","article-title":"Antithrombotic effects of combined PAR (Protease-Activated Receptor)-4 antagonism and factor Xa inhibition","volume":"40","author":"Meah","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.hoc.2026.09.013_bib59","doi-asserted-by":"crossref","DOI":"10.1080\/09537104.2023.2222846","article-title":"First-in-human study to assess the safety, pharmacokinetics, and pharmacodynamics of BMS-986141, a novel, reversible, small-molecule, PAR4 agonist in Non-Japanese and Japanese healthy participants","volume":"34","author":"Merali","year":"2023","journal-title":"Platelets"},{"issue":"4","key":"10.1016\/j.hoc.2026.09.013_bib60","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1161\/ATVBAHA.123.320448","article-title":"PAR4 antagonism in patients with coronary artery disease receiving antiplatelet therapies","volume":"44","author":"Nash","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.hoc.2026.09.013_bib63","article-title":"In vitro assessment and phase I randomized clinical trial of anfibatide a snake venom derived anti-thrombotic agent targeting human platelet GPIb\u03b1","volume":"11","author":"Li","year":"2021","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.hoc.2026.09.013_bib64","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/phar.2620","article-title":"Safety and efficacy of a platelet glycoprotein Ib inhibitor for patients with non-ST segment elevation myocardial infarction: a phase Ib\/IIa study","volume":"41","author":"Zheng","year":"2021","journal-title":"Pharmacotherapy"},{"issue":"10","key":"10.1016\/j.hoc.2026.09.013_bib61","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1161\/ATVBAHA.117.309868","article-title":"First selective 12-LOX inhibitor, ML355, impairs thrombus formation and vessel occlusion in vivo with minimal effects on hemostasis","volume":"37","author":"Adili","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.hoc.2026.09.013_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115297","article-title":"Novel approaches to antiplatelet therapy","volume":"206","author":"Gresele","year":"2022","journal-title":"Biochem Pharmacol"},{"issue":"7","key":"10.1016\/j.hoc.2026.09.013_bib66","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/ng.604","article-title":"Genome-wide meta-analyses identifies seven loci associated with platelet aggregation in response to agonists","volume":"42","author":"Johnson","year":"2010","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.hoc.2026.09.013_bib67","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1038\/s41467-021-23470-9","article-title":"Genome sequencing unveils a regulatory landscape of platelet reactivity","volume":"12","author":"Keramati","year":"2021","journal-title":"Nat Commun"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826001231?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826001231?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:15:08Z","timestamp":1792786508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858826001231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":67,"alternative-id":["S0889858826001231"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2026.09.013","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging Antiplatelet Agents","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2026.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}